Safety and immunogenicity of a candidate HIV-1 vaccine in healthy adults: recombinant glycoprotein (rgp) 120. A randomized, double-blind trial. NIAID AIDS Vaccine Evaluation Group. Ann Intern Med, 125(4), 270-9. presented at the 1996 Aug 15. doi:10.7326/0003-4819-125-4-199608150-00003. (1996).
Safety profile of phase I and II preventive HIV type 1 envelope vaccination: experience of the NIAID AIDS Vaccine Evaluation Group. AIDS Res Hum Retroviruses, 13(14), 1163-77. presented at the 1997 Sep 20. doi:10.1089/aid.1997.13.1163. (1997).
Analysis of intercurrent human immunodeficiency virus type 1 infections in phase I and II trials of candidate AIDS vaccines. AIDS Vaccine Evaluation Group, and the Correlates of HIV Immune Protection Group. J Infect Dis, 177(2), 310-9. presented at the 1998 Feb. doi:10.1086/514209. (1998).
Immunization with recombinant canarypox vectors expressing membrane-anchored glycoprotein 120 followed by glycoprotein 160 boosting fails to generate antibodies that neutralize R5 primary isolates of human immunodeficiency virus type 1. AIDS Res Hum Retroviruses, 16(18), 2019-35. presented at the 2000 Dec 10. doi:10.1089/088922200750054756. (2000).